Help paying · Medicare negotiated price · pharmacy cost · cycle 2026
Jardiance (empagliflozin): where help paying exists, what Medicare negotiated and what pharmacies pay
2 assistance programs list empagliflozin, each with its income ceiling and when we read it. Medicare's negotiated price for a 30-day supply is $197 (in force since January 1, 2026). A scheduled change takes it to $202 on January 1, 2027. Per unit, the negotiated price is 61% of NADAC, the pharmacy acquisition benchmark. The FDA's enforcement reports name this drug's packages in 2 recall entries. ClinicalTrials.gov lists 94 recruiting trials that name empagliflozin.
One package, side by side
Price per unit for one package of Jardiance. The negotiated price applies to Medicare Part D; NADAC is a survey of what retail pharmacies pay to buy the drug.
Swipe to read across
Every package we can price
Per-unit prices (per each unit, as the files state). "Scheduled" is a price the CMS file already dates for the future.
| NDC | Product | Unit | Negotiated now | Scheduled | NADAC | Share |
|---|---|---|---|---|---|---|
| 00597-0152-30 | Jardiance 10mg Tablets 30s | EA | $6.79 | $6.98 | $11.19 | 61% |
| 00597-0152-37 | Jardiance (3x10) Blister Cards | EA | $6.79 | $6.98 | $11.19 | 61% |
| 00597-0152-90 | Jardiance 10mg Tablets 90s | EA | $6.79 | $6.98 | $11.19 | 61% |
| 00597-0153-30 | Jardiance 25mg Tablets 30s | EA | $6.79 | $6.98 | $11.19 | 61% |
| 00597-0153-37 | Jardiance (3x10) Blister Cards | EA | $6.79 | $6.98 | $11.19 | 61% |
| 00597-0153-90 | Jardiance 25mg Tablets 90s | EA | $6.79 | $6.98 | $11.19 | 61% |
When could a generic arrive
Each date below is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
| Application | Product | Latest listed patent expiry | Latest listed exclusivity expiry | Latest of the two | Set by |
|---|---|---|---|---|---|
| NDA204629 | Jardiance (3x10) Blister Cards, Jardiance 10mg Tablets 30s, Jardiance 10mg Tablets 90s, Jardiance 25mg Tablets 30s and 1 more | December 11, 2034 | December 20, 2026 | December 11, 2034 | patent 9949998 with its pediatric extension; 56 dated entries listed |
Source: FDA Orange Book data files, edition September 2026, read November 7, 2026; patent listings are as submitted by applicants and not verified by FDA. FDA data file.
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Jardiance of $11.44 billion in 2024, across 11,368,280 claims and 2,543,331 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $11.44 billion | 11,368,280 | 2,543,331 | $1,006 |
| 2023 | $8.84 billion | 8,153,238 | 1,882,768 | $1,084 |
| 2022 | $5.85 billion | 5,653,254 | 1,321,067 | $1,035 |
| 2021 | $3.74 billion | 3,824,726 | 884,516 | $977 |
| 2020 | $2.38 billion | 2,677,192 | 594,859 | $888 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
Rare-disease (orphan) designations
The FDA's orphan drug database lists 1 designation for empagliflozin. A designation is not an approval and not a statement that the drug treats the condition; the status column is the database's own.
| Designated | Designated use | Status | Sponsor |
|---|---|---|---|
| November 2, 2026 | treatment of glycogen storage disease type 1b (GSD1b) | Designated | Vitalis Scientia LLC |
Source: FDA Orphan Drug Designations and Approvals database, read November 7, 2026. FDA orphan drug search.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2025, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 4 states with the largest reimbursement are shown. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| OH | 190 | $140,941 | Fee-for-service only |
| LA | 91 | $45,570 | All record types |
| MO | 120 | $42,419 | All record types |
| MN | 95 | $37,611 | Fee-for-service only |
Where the publisher suppresses small managed-care cells, a state's figure covers fee-for-service claims only and understates use (3 state and package figures are marked that way here). A state missing from the table means its figures were suppressed or not reported, not zero use. 236 older-year figures are held and left out of the table.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2025, modified 2026-07-13T15:28:32Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Where help paying exists
Programs in our finder that list empagliflozin. Each shows its income ceiling, when we read it and whether we checked it against the program's own document. Eligibility is decided by the program, not by us.
- Boehringer Ingelheim Cares Foundation manufacturer
Income at or below 250% FPL ($39,900 for one person), or 200% ($31,920) for the Respimat inhalers. Since 15 October 2026 no new Medicare Part D or Advantage enrollments for its primary care products, including Jardiance
Ceiling read on the program's own document, November 6, 2026.Status. No new patient enrollments for individuals with Medicare Part D or Medicare Advantage prescription drug coverage for Boehringer Ingelheim primary care products (Combivent Respimat, Glyxambi, Jardiance, Jentadueto, Jentadueto XR, Spiriva Respimat, Stiolto Respimat, Synjardy, Synjardy XR, Tradjenta, Trijardy XR). Part D patients actively enrolled as of 2026-10-15 continue through their current enrollment period and may be eligible in 2027 only after annual re-enrollment. Product removals: Cyltezo 2026-07-15; OFEV 2026-09-11 (active patients continue through the end of their enrollment or 2027-12-31); no new enrollments for Aptivus, Atrovent and Striverdi from 2026-10-15. (read November 6, 2026)
- Jardiance Savings Card (BI/Lilly) manufacturer
No income limit in our data
Figure not yet re-read on the program's own page.
Check where your income sits against each ceiling: open the assistance finder. See what has changed and when we last verified each program on the program status board.
Label changes
The FDA file lists no non-manufacturing label change for these applications since November 11, 2025. The most recent one it lists is dated October 24, 2025 (Labeling).
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Safety notices
FDA enforcement report entries that name a package of Jardiance by its NDC: 2 entries, newest first. FDA assigns each a class by health risk: Class I is the most serious and Class III the least. An entry records what the recalling firm reported and FDA classified; it is not advice about any package you hold.
| Reported | Class | Status | Recalling firm | Reason (shortened) | Packages named |
|---|---|---|---|---|---|
| January 3, 2024D-0185-2024 | Class II | Terminated | CARDINAL HEALTHCARE | CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions. | 6 |
| March 29, 2023D-0468-2023 | Class II | Terminated | Boehringer Ingelheim Pharmaceuticals, Inc. | Labeling: Label Mix-up | 6 |
Source: openFDA drug enforcement reports, file read November 7, 2026. openFDA data file. All recent recalls across these drugs: drug recalls feed.
Clinical trials recruiting
ClinicalTrials.gov lists 94 interventional trials that name empagliflozin and are recruiting, and 29 more not yet recruiting. By phase: Phase 4: 29, Phase 3: 18, Phase 2: 18, Early phase 1: 8, Phase 1: 7, Not applicable: 6, PHASE1/PHASE2: 4, PHASE2/PHASE3: 4. The 10 most recently updated are below. A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
| Trial | Title and conditions | Phase | Lead sponsor | Last updated | Countries |
|---|---|---|---|---|---|
| NCT03424005 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerMetastatic Breast Cancer | Phase 1 / Phase 2 | Hoffmann-La Roche | November 6, 2026 | United States, Australia, France and 6 more |
| NCT05972564 | The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial FunctionObesity; Metabolic Syndrome | Phase 1 / Phase 2 | Vanderbilt University Medical Center | November 5, 2026 | United States |
| NCT07038356 | Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart FailureAcute Decompensated Heart Failure (ADHF) | Phase 3 | Christian Schulze | November 4, 2026 | Germany |
| NCT07845630 | A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the BodyHealthy | Phase 1 | Boehringer Ingelheim | October 29, 2026 | Germany |
| NCT06424288 | A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailureHeart Failure | Phase 3 | Boehringer Ingelheim | October 28, 2026 | United States, Argentina, Australia and 7 more |
| NCT06935370 | A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartHeart Failure | Phase 3 | Boehringer Ingelheim | October 28, 2026 | United States, Argentina, Belgium and 7 more |
| NCT06249932 | Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal DiseaseHeart Failure With Reduced Ejection Fraction; End Stage Renal Disease on Dialysis | Phase 4 | National Taiwan University Hospital | October 28, 2026 | Taiwan |
| NCT07064473 | EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseDiabetes Mellitus, Type 2; Hypertension; Cardiovascular Diseases | Phase 3 | Boehringer Ingelheim | October 28, 2026 | United States, Argentina, Australia and 7 more |
| NCT06653738 | Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE PreventionKidney Stone; Nephrolithiasis; Dietary Exposure | Phase 3 | Insel Gruppe AG, University Hospital Bern | October 23, 2026 | France, Germany, Italy and 1 more |
| NCT06483074 | Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis PatientsEnd Stage Renal Disease on Dialysis; Peritoneal Dialysis Complication; Sodium-glucose Cotransporter-2 Inhibitor | Phase 2 | Chinese University of Hong Kong | October 22, 2026 | Hong Kong |
Source: ClinicalTrials.gov, registry data processed November 6, 2026, summarized and trimmed by OmniRx. Search on ClinicalTrials.gov.
Questions
What is the Medicare negotiated price of Jardiance?
For a 30-day supply the price CMS published is $197, in force since January 1, 2026. The CMS file also schedules $202 from January 1, 2027. This is a price CMS agreed with the manufacturer for Medicare Part D, not what a person pays at the counter.
How does the negotiated price compare with what pharmacies pay?
Across the 6 packages where both CMS files give a price per unit, the median negotiated price is 61% of NADAC, the pharmacy acquisition benchmark (NADAC as of November 4, 2026). NADAC is a survey average, not a quote.
Is there help paying for Jardiance?
2 assistance programs list it in our finder. Eligibility depends on income, coverage and the program's current rules; each program's own page decides.
When could a generic version of Jardiance arrive?
For Jardiance, the FDA's Orange Book (edition September 2026) lists these latest patent or exclusivity expiry dates by application: NDA204629, December 11, 2034. Each date is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
Can I join a clinical trial for Jardiance?
ClinicalTrials.gov lists 94 recruiting interventional trials that name empagliflozin (registry data processed November 6, 2026). A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
How much does Medicare Part D spend on Jardiance?
CMS's Medicare Part D spending dataset reports gross spending on Jardiance of $11.44 billion in 2024, across 11,368,280 claims and 2,543,331 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns price, generic-entry upper bound, label history, recalls, trials, assistance, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/jardiance.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. CMS Medicare Drug Price Negotiation Program data file (read November 6, 2026; the CMS page states no licence or restriction); CMS NADAC from data.medicaid.gov under the labels in the OmniRx licence ledger; program details read from each program's own pages; CMS Medicare Part D spending by drug; FDA Drugs@FDA and Orange Book data files; openFDA drug enforcement reports; ClinicalTrials.gov registry data. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.